Cargando…
The Indigenous Australian Human Papillomavirus (HPV) Cohort Study 2, Continuation for 5 to 10 Years: Protocol for a Longitudinal Study
BACKGROUND: Human papillomavirus (HPV) infection, a common sexually transmitted disease, is associated with cancers of the cervix, vulva, vagina, penis, anus, and head and neck. Oropharyngeal squamous cell carcinoma (OPSCC; throat cancer) is a type of cancer involving the head and neck area that is...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
JMIR Publications
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10233440/ https://www.ncbi.nlm.nih.gov/pubmed/37195752 http://dx.doi.org/10.2196/44593 |
_version_ | 1785052234204053504 |
---|---|
author | Hedges, Joanne Sethi, Sneha Garvey, Gail Whop, Lisa J Canfell, Karen Dodd, Zell Larkins, Priscilla Antonsson, Annika Smith, Megan A Mittinty, Murthy Leane, Catherine Reid, Nicolas Ooi, Eng H Ju, Xiangqun Logan, Richard Jamieson, Lisa |
author_facet | Hedges, Joanne Sethi, Sneha Garvey, Gail Whop, Lisa J Canfell, Karen Dodd, Zell Larkins, Priscilla Antonsson, Annika Smith, Megan A Mittinty, Murthy Leane, Catherine Reid, Nicolas Ooi, Eng H Ju, Xiangqun Logan, Richard Jamieson, Lisa |
author_sort | Hedges, Joanne |
collection | PubMed |
description | BACKGROUND: Human papillomavirus (HPV) infection, a common sexually transmitted disease, is associated with cancers of the cervix, vulva, vagina, penis, anus, and head and neck. Oropharyngeal squamous cell carcinoma (OPSCC; throat cancer) is a type of cancer involving the head and neck area that is rapidly increasing across the globe. There are higher rates of OPSCC among Indigenous populations relative to non–Indigenous Australian populations, although the HPV-attributable fraction remains unknown. For the first time at a global level, we plan to extend an Indigenous Australian adult cohort to monitor, screen, and ultimately prevent HPV-associated OPSCC and to undertake extensive cost-effectiveness modelling around HPV vaccination. OBJECTIVE: This study aims to (1) extend follow-up to a minimum of 7 years post recruitment to describe the prevalence, incidence, clearance, and persistence of oral HPV infection; and (2) conduct clinical examinations of the head and neck, oral cavity, and oropharynx and collect saliva samples for early-stage OPSCC testing. METHODS: We will continue to implement a longitudinal design for the next study phase, where we will ascertain the prevalence, incidence, clearance, and persistence of oral HPV infection at 48, 60, and 72 months; undertake clinical examinations/saliva assessments to detect early-stage OPSCC; and refer for treatment. The primary outcome measures are changes in oral HPV infection status, biomarker measures of early HPV-related cancer, and clinical evidence of early-stage OPSCC. RESULTS: Participant 48-month follow-up will commence in January 2023. The first results are expected to be submitted for publication 1 year after 48-month follow-up begins. CONCLUSIONS: Our findings have potential to change the way in which OPSCC among Australian Indigenous adults is managed, with desired impacts including cost-savings on expensive cancer treatments; improved nutritional, social, and emotional outcomes; and improved quality of life for both Indigenous adults and the Indigenous community more broadly. Continuing a large, representative Indigenous adult cohort to track oral HPV infection and monitor early OPSCC is essential to yield critical information to include in the management armamentarium of health and well-being recommendations for Australia’s First Nations. INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): PRR1-10.2196/44593 |
format | Online Article Text |
id | pubmed-10233440 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | JMIR Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-102334402023-06-02 The Indigenous Australian Human Papillomavirus (HPV) Cohort Study 2, Continuation for 5 to 10 Years: Protocol for a Longitudinal Study Hedges, Joanne Sethi, Sneha Garvey, Gail Whop, Lisa J Canfell, Karen Dodd, Zell Larkins, Priscilla Antonsson, Annika Smith, Megan A Mittinty, Murthy Leane, Catherine Reid, Nicolas Ooi, Eng H Ju, Xiangqun Logan, Richard Jamieson, Lisa JMIR Res Protoc Protocol BACKGROUND: Human papillomavirus (HPV) infection, a common sexually transmitted disease, is associated with cancers of the cervix, vulva, vagina, penis, anus, and head and neck. Oropharyngeal squamous cell carcinoma (OPSCC; throat cancer) is a type of cancer involving the head and neck area that is rapidly increasing across the globe. There are higher rates of OPSCC among Indigenous populations relative to non–Indigenous Australian populations, although the HPV-attributable fraction remains unknown. For the first time at a global level, we plan to extend an Indigenous Australian adult cohort to monitor, screen, and ultimately prevent HPV-associated OPSCC and to undertake extensive cost-effectiveness modelling around HPV vaccination. OBJECTIVE: This study aims to (1) extend follow-up to a minimum of 7 years post recruitment to describe the prevalence, incidence, clearance, and persistence of oral HPV infection; and (2) conduct clinical examinations of the head and neck, oral cavity, and oropharynx and collect saliva samples for early-stage OPSCC testing. METHODS: We will continue to implement a longitudinal design for the next study phase, where we will ascertain the prevalence, incidence, clearance, and persistence of oral HPV infection at 48, 60, and 72 months; undertake clinical examinations/saliva assessments to detect early-stage OPSCC; and refer for treatment. The primary outcome measures are changes in oral HPV infection status, biomarker measures of early HPV-related cancer, and clinical evidence of early-stage OPSCC. RESULTS: Participant 48-month follow-up will commence in January 2023. The first results are expected to be submitted for publication 1 year after 48-month follow-up begins. CONCLUSIONS: Our findings have potential to change the way in which OPSCC among Australian Indigenous adults is managed, with desired impacts including cost-savings on expensive cancer treatments; improved nutritional, social, and emotional outcomes; and improved quality of life for both Indigenous adults and the Indigenous community more broadly. Continuing a large, representative Indigenous adult cohort to track oral HPV infection and monitor early OPSCC is essential to yield critical information to include in the management armamentarium of health and well-being recommendations for Australia’s First Nations. INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): PRR1-10.2196/44593 JMIR Publications 2023-05-17 /pmc/articles/PMC10233440/ /pubmed/37195752 http://dx.doi.org/10.2196/44593 Text en ©Joanne Hedges, Sneha Sethi, Gail Garvey, Lisa J Whop, Karen Canfell, Zell Dodd, Priscilla Larkins, Annika Antonsson, Megan A Smith, Murthy Mittinty, Catherine Leane, Nicolas Reid, Eng H Ooi, Xiangqun Ju, Richard Logan, Lisa Jamieson. Originally published in JMIR Research Protocols (https://www.researchprotocols.org), 17.05.2023. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in JMIR Research Protocols, is properly cited. The complete bibliographic information, a link to the original publication on https://www.researchprotocols.org, as well as this copyright and license information must be included. |
spellingShingle | Protocol Hedges, Joanne Sethi, Sneha Garvey, Gail Whop, Lisa J Canfell, Karen Dodd, Zell Larkins, Priscilla Antonsson, Annika Smith, Megan A Mittinty, Murthy Leane, Catherine Reid, Nicolas Ooi, Eng H Ju, Xiangqun Logan, Richard Jamieson, Lisa The Indigenous Australian Human Papillomavirus (HPV) Cohort Study 2, Continuation for 5 to 10 Years: Protocol for a Longitudinal Study |
title | The Indigenous Australian Human Papillomavirus (HPV) Cohort Study 2, Continuation for 5 to 10 Years: Protocol for a Longitudinal Study |
title_full | The Indigenous Australian Human Papillomavirus (HPV) Cohort Study 2, Continuation for 5 to 10 Years: Protocol for a Longitudinal Study |
title_fullStr | The Indigenous Australian Human Papillomavirus (HPV) Cohort Study 2, Continuation for 5 to 10 Years: Protocol for a Longitudinal Study |
title_full_unstemmed | The Indigenous Australian Human Papillomavirus (HPV) Cohort Study 2, Continuation for 5 to 10 Years: Protocol for a Longitudinal Study |
title_short | The Indigenous Australian Human Papillomavirus (HPV) Cohort Study 2, Continuation for 5 to 10 Years: Protocol for a Longitudinal Study |
title_sort | indigenous australian human papillomavirus (hpv) cohort study 2, continuation for 5 to 10 years: protocol for a longitudinal study |
topic | Protocol |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10233440/ https://www.ncbi.nlm.nih.gov/pubmed/37195752 http://dx.doi.org/10.2196/44593 |
work_keys_str_mv | AT hedgesjoanne theindigenousaustralianhumanpapillomavirushpvcohortstudy2continuationfor5to10yearsprotocolforalongitudinalstudy AT sethisneha theindigenousaustralianhumanpapillomavirushpvcohortstudy2continuationfor5to10yearsprotocolforalongitudinalstudy AT garveygail theindigenousaustralianhumanpapillomavirushpvcohortstudy2continuationfor5to10yearsprotocolforalongitudinalstudy AT whoplisaj theindigenousaustralianhumanpapillomavirushpvcohortstudy2continuationfor5to10yearsprotocolforalongitudinalstudy AT canfellkaren theindigenousaustralianhumanpapillomavirushpvcohortstudy2continuationfor5to10yearsprotocolforalongitudinalstudy AT doddzell theindigenousaustralianhumanpapillomavirushpvcohortstudy2continuationfor5to10yearsprotocolforalongitudinalstudy AT larkinspriscilla theindigenousaustralianhumanpapillomavirushpvcohortstudy2continuationfor5to10yearsprotocolforalongitudinalstudy AT antonssonannika theindigenousaustralianhumanpapillomavirushpvcohortstudy2continuationfor5to10yearsprotocolforalongitudinalstudy AT smithmegana theindigenousaustralianhumanpapillomavirushpvcohortstudy2continuationfor5to10yearsprotocolforalongitudinalstudy AT mittintymurthy theindigenousaustralianhumanpapillomavirushpvcohortstudy2continuationfor5to10yearsprotocolforalongitudinalstudy AT leanecatherine theindigenousaustralianhumanpapillomavirushpvcohortstudy2continuationfor5to10yearsprotocolforalongitudinalstudy AT reidnicolas theindigenousaustralianhumanpapillomavirushpvcohortstudy2continuationfor5to10yearsprotocolforalongitudinalstudy AT ooiengh theindigenousaustralianhumanpapillomavirushpvcohortstudy2continuationfor5to10yearsprotocolforalongitudinalstudy AT juxiangqun theindigenousaustralianhumanpapillomavirushpvcohortstudy2continuationfor5to10yearsprotocolforalongitudinalstudy AT loganrichard theindigenousaustralianhumanpapillomavirushpvcohortstudy2continuationfor5to10yearsprotocolforalongitudinalstudy AT jamiesonlisa theindigenousaustralianhumanpapillomavirushpvcohortstudy2continuationfor5to10yearsprotocolforalongitudinalstudy AT hedgesjoanne indigenousaustralianhumanpapillomavirushpvcohortstudy2continuationfor5to10yearsprotocolforalongitudinalstudy AT sethisneha indigenousaustralianhumanpapillomavirushpvcohortstudy2continuationfor5to10yearsprotocolforalongitudinalstudy AT garveygail indigenousaustralianhumanpapillomavirushpvcohortstudy2continuationfor5to10yearsprotocolforalongitudinalstudy AT whoplisaj indigenousaustralianhumanpapillomavirushpvcohortstudy2continuationfor5to10yearsprotocolforalongitudinalstudy AT canfellkaren indigenousaustralianhumanpapillomavirushpvcohortstudy2continuationfor5to10yearsprotocolforalongitudinalstudy AT doddzell indigenousaustralianhumanpapillomavirushpvcohortstudy2continuationfor5to10yearsprotocolforalongitudinalstudy AT larkinspriscilla indigenousaustralianhumanpapillomavirushpvcohortstudy2continuationfor5to10yearsprotocolforalongitudinalstudy AT antonssonannika indigenousaustralianhumanpapillomavirushpvcohortstudy2continuationfor5to10yearsprotocolforalongitudinalstudy AT smithmegana indigenousaustralianhumanpapillomavirushpvcohortstudy2continuationfor5to10yearsprotocolforalongitudinalstudy AT mittintymurthy indigenousaustralianhumanpapillomavirushpvcohortstudy2continuationfor5to10yearsprotocolforalongitudinalstudy AT leanecatherine indigenousaustralianhumanpapillomavirushpvcohortstudy2continuationfor5to10yearsprotocolforalongitudinalstudy AT reidnicolas indigenousaustralianhumanpapillomavirushpvcohortstudy2continuationfor5to10yearsprotocolforalongitudinalstudy AT ooiengh indigenousaustralianhumanpapillomavirushpvcohortstudy2continuationfor5to10yearsprotocolforalongitudinalstudy AT juxiangqun indigenousaustralianhumanpapillomavirushpvcohortstudy2continuationfor5to10yearsprotocolforalongitudinalstudy AT loganrichard indigenousaustralianhumanpapillomavirushpvcohortstudy2continuationfor5to10yearsprotocolforalongitudinalstudy AT jamiesonlisa indigenousaustralianhumanpapillomavirushpvcohortstudy2continuationfor5to10yearsprotocolforalongitudinalstudy |